GLP-1R Agonists Found Effective for Weight Loss

Glucagon-like peptide-1 receptor agonists also reduce blood pressure and total cholesterol

WEDNESDAY, Jan. 11 (HealthDay News) -- Treatment with glucagon-like peptide-1 receptor (GLP-1R) agonists for at least 20 weeks leads to weight loss in obese or overweight patients with or without type 2 diabetes mellitus, according to a study published online Jan. 11 in BMJ.

Tina Vilsbøll, M.D., of the University of Copenhagen in Denmark, and colleagues conducted a systematic review and meta-analysis. They included 21 randomized, controlled trials with 6,411 adults with a body mass index of ≥25 kg/m², with or without type 2 diabetes mellitus. The participants received either exenatide twice daily, exenatide once weekly, or liraglutide once daily at clinically relevant doses for at least 20 weeks.

The researchers found the GLP-1R agonist groups achieved greater weight loss than the control groups (weighted mean difference, −2.9 kg; 95 percent confidence interval, −3.6 to −2.2). There was evidence of intertrial heterogeneity but, in regression analyses, no evidence of bias or small study effects was found. Beneficial effects of GLP-1R agonists were seen for systolic and diastolic blood pressure, plasma concentrations of cholesterol, and glycemic control, but there were no significant effects seen for plasma concentrations of liver enzymes.

"The present review provides evidence that treatment with GLP-1R agonists leads to weight loss in overweight or obese patients with or without type 2 diabetes mellitus," the authors write.

Full Text
Editorial (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles

What internal motivators drive RNs to pursue a BSN?
Nursing2014 , October 2014
Free access will expire on November 24, 2014.


Breast Cancer Risk Assessment in Primary Care
MCN, The American Journal of Maternal/Child Nursing, September/October 2014
Free access will expire on November 10, 2014.


Nurses spurring innovation
Nursing Management, October 2014
Free access will expire on November 10, 2014.


More Recommended Articles

Subscribe to Recommended Articles

Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events